146 related articles for article (PubMed ID: 23762619)
1. A New Strategy to Find Targets for Anticancer Therapy: Chemokine CXCL14/BRAK Is a Multifunctional Tumor Suppressor for Head and Neck Squamous Cell Carcinoma.
Hata R
ISRN Otolaryngol; 2012; 2012():797619. PubMed ID: 23762619
[TBL] [Abstract][Full Text] [Related]
2. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells.
Ozawa S; Kato Y; Komori R; Maehata Y; Kubota E; Hata R
Biochem Biophys Res Commun; 2006 Sep; 348(2):406-12. PubMed ID: 16884687
[TBL] [Abstract][Full Text] [Related]
3. Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected].
Izukuri K; Suzuki K; Yajima N; Ozawa S; Ito S; Kubota E; Hata R
Transgenic Res; 2010 Dec; 19(6):1109-17. PubMed ID: 20333465
[TBL] [Abstract][Full Text] [Related]
4. Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
Ozawa S; Kato Y; Ito S; Komori R; Shiiki N; Tsukinoki K; Ozono S; Maehata Y; Taguchi T; Imagawa-Ishiguro Y; Tsukuda M; Kubota E; Hata R
Cancer Sci; 2009 Nov; 100(11):2202-9. PubMed ID: 19673887
[TBL] [Abstract][Full Text] [Related]
5. Expression of tumour-suppressing chemokine BRAK/CXCL14 reduces cell migration rate of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated focal adhesions in vitro.
Sato K; Ozawa S; Izukuri K; Kato Y; Hata R
Cell Biol Int; 2010 Apr; 34(5):513-22. PubMed ID: 20067447
[TBL] [Abstract][Full Text] [Related]
6. Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma.
Miyamoto C; Maehata Y; Motohashi K; Ozawa S; Ikoma T; Hidaka K; Wada-Takahashi S; Takahashi SS; Yoshino F; Yoshida A; Kubota E; Hata R; Lee MC
Biomed Res; 2014; 35(6):381-8. PubMed ID: 25743344
[TBL] [Abstract][Full Text] [Related]
7. Reactive oxygen species (ROS) reduce the expression of BRAK/CXCL14 in human head and neck squamous cell carcinoma cells.
Maehata Y; Ozawa S; Kobayashi K; Kato Y; Yoshino F; Miyamoto C; Izukuri K; Kubota E; Hata R; Lee MC
Free Radic Res; 2010 Aug; 44(8):913-24. PubMed ID: 20815772
[TBL] [Abstract][Full Text] [Related]
8. Expression of a chemokine BRAK/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vivo.
Ito S; Ozawa S; Ikoma T; Yajima N; Kiyono T; Hata R
Biomed Res; 2010 Jun; 31(3):199-206. PubMed ID: 20622470
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of proximal promoter of gene for human BRAK/CXCL14, a tumor-suppressing chemokine.
Komori R; Ozawa S; Kato Y; Shinji H; Kimoto S; Hata R
Biomed Res; 2010 Apr; 31(2):123-31. PubMed ID: 20460740
[TBL] [Abstract][Full Text] [Related]
10. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.
Shurin GV; Ferris RL; Tourkova IL; Perez L; Lokshin A; Balkir L; Collins B; Chatta GS; Shurin MR
J Immunol; 2005 May; 174(9):5490-8. PubMed ID: 15843547
[TBL] [Abstract][Full Text] [Related]
11. BRAK/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse.
Ozawa S; Kato Y; Kubota E; Hata R
Biomed Res; 2009 Oct; 30(5):315-8. PubMed ID: 19887729
[TBL] [Abstract][Full Text] [Related]
12. Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK.
Miyamoto C; Maehata Y; Ozawa S; Ikoma T; Kubota E; Izukuri K; Kato Y; Hata R; Lee MC
J Pharmacol Sci; 2012; 120(3):241-9. PubMed ID: 23099322
[TBL] [Abstract][Full Text] [Related]
13. Human p38 delta MAP kinase mediates UV irradiation induced up-regulation of the gene expression of chemokine BRAK/CXCL14.
Ozawa S; Ito S; Kato Y; Kubota E; Hata R
Biochem Biophys Res Commun; 2010 Jun; 396(4):1060-4. PubMed ID: 20478268
[TBL] [Abstract][Full Text] [Related]
14. C-X-C Motif Chemokine Ligand 14 is a Unique Multifunctional Regulator of Tumor Progression.
Yang XY; Ozawa S; Kato Y; Maehata Y; Izukuri K; Ikoma T; Kanamori K; Akasaka T; Suzuki K; Iwabuchi H; Kurata SI; Katoh I; Sakurai T; Kiyono T; Hata RI
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31014014
[TBL] [Abstract][Full Text] [Related]
15. Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma.
Kondo T; Ozawa S; Ikoma T; Yang XY; Kanamori K; Suzuki K; Iwabuchi H; Maehata Y; Miyamoto C; Taguchi T; Kiyono T; Kubota E; Hata RI
Oncogenesis; 2016 Jul; 5(7):e240. PubMed ID: 27399917
[TBL] [Abstract][Full Text] [Related]
16. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue.
Frederick MJ; Henderson Y; Xu X; Deavers MT; Sahin AA; Wu H; Lewis DE; El-Naggar AK; Clayman GL
Am J Pathol; 2000 Jun; 156(6):1937-50. PubMed ID: 10854217
[TBL] [Abstract][Full Text] [Related]
17. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
Wang H; Nan S; Wang Y; Xu C
J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
[TBL] [Abstract][Full Text] [Related]
18. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells.
Shellenberger TD; Wang M; Gujrati M; Jayakumar A; Strieter RM; Burdick MD; Ioannides CG; Efferson CL; El-Naggar AK; Roberts D; Clayman GL; Frederick MJ
Cancer Res; 2004 Nov; 64(22):8262-70. PubMed ID: 15548693
[TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo.
Wang W; Huang P; Zhang L; Wei J; Xie Q; Sun Q; Zhou X; Xie H; Zhou L; Zheng S
Cancer Sci; 2013 Nov; 104(11):1523-31. PubMed ID: 24033560
[TBL] [Abstract][Full Text] [Related]
20. Calcium-calmodulin signaling induced by epithelial cell differentiation upregulates BRAK/CXCL14 expression via the binding of SP1 to the BRAK promoter region.
Ikoma T; Ozawa S; Suzuki K; Kondo T; Maehata Y; Lee MC; Hata R; Kubota E
Biochem Biophys Res Commun; 2012 Apr; 420(2):217-22. PubMed ID: 22382027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
